Hemostemix Price To Sales Ratio Over Time

HEM Stock  CAD 0.08  0.01  5.88%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Hemostemix Performance and Hemostemix Correlation.
  
Common Stock Shares Outstanding is likely to climb to about 86.6 M in 2024, whereas Net Loss is likely to drop (4.9 M) in 2024.
Please note, there is a significant difference between Hemostemix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hemostemix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hemostemix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Price To Sales Ratio Analysis

Compare Hemostemix and related stocks such as Vaxil Bio, VentriPoint Diagnostics, and MedMira Price To Sales Ratio Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
VXL0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
VPT10210243.285613877.731610615.755536414862.5746186618618941988
MIR81014.37149.799412.20715.511511.668826.428222.360212.482130136.838692.933145167175
THRM237259259259259115299316591K21.1 K262406431409
DM1341341341341341341341343.57541.3182.87621.02150.95240.76670.73

Hemostemix and related stocks such as Vaxil Bio, VentriPoint Diagnostics, and MedMira Price To Sales Ratio description

Price to Sales Ratio is figured by comparing Hemostemix stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Hemostemix sales, a figure that is much harder to manipulate than other Hemostemix multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

My Equities

My Current Equities and Potential Positions

Hemostemix
HEM
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Business Address707-7th Avenue SW,
ExchangeTSX Venture Exchange
CAD 0.08

Additional Tools for Hemostemix Stock Analysis

When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.